The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects (1928)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2012 by Kaleida Health.
Recruitment status was  Active, not recruiting
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Paresh Dandona, MD, Kaleida Health Identifier:
First received: April 10, 2008
Last updated: December 17, 2012
Last verified: December 2012

Sitagliptin is a new oral hypoglycemic anti-diabetic drug used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. Sitagliptin has been shown to have fewer side effects in the control of blood glucose values.

Obesity and diabetes are states of increased inflammation and can influence the free radicals and inflammatory markers (chemicals in the blood which increase due to inflammation in the body) and are also major risk factors for atherosclerotic disease. In this study we want to see the effect of sitagliptin on these markers. We believe that Sitagliptin may exert an anti-inflammatory effect in the human. The purpose of this study is to determine if the addition of sitagliptin to diabetic patients will provide added benefit. We believe that sitagliptin provides these added benefits by suppressing free radicals (charged substances that cause damage to the body) and inflammation.

Condition Intervention
Type 2 Diabetes
Drug: Januvia (Sitagliptin) 100 mg
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects

Resource links provided by NLM:

Further study details as provided by Kaleida Health:

Primary Outcome Measures:
  • To investigate that therapy with sitagliptin orally daily (100 mg) for 12 weeks decreases reactive oxygen species (ROS) generation by MNC, protein and mRNA expression of p47phox subunit of NADPH oxidase, in MNC's of obese type 2 diabetic patients [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • oxidative stress [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    To investigate that therapy with sitagliptin orally daily (100 mg) for 12 weeks decreases oxidized lipids (9-hydroxyoctadecadienoicacid (9-HODE) and 13-HODE) in plasma and F2-isoprostane in urine of obese type 2 diabetic patients

Estimated Enrollment: 40
Study Start Date: March 2008
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Januvia 100mg
The first group will be started on 100 mg sitagliptin daily for 12 weeks
Drug: Januvia (Sitagliptin) 100 mg
The first group will be started on 100 mg sitagliptin daily for 12 weeks
Other Name: januvia
Placebo Comparator: placebo
will be placed on a placebo for 12 weeks.
Drug: Placebo
will be placed on a placebo for 12 weeks.


Ages Eligible for Study:   20 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females with age 20-75 years inclusive.
  • Type 2 diabetes
  • Males and Females BMI > 30
  • Subjects on statins, ACE inhibitors, thiazolidenediones and antioxidants will be allowed as long as they are on stable doses of these compounds and the dosage in not changed during the course of study.
  • BP under control -No change required to BP medications
  • HbA1c > 7%

Exclusion Criteria:

  • Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks
  • Pregnancy
  • Hepatic disease (abnormal LFT's),Renal impairment (serum creatinine > 1.5),
  • Participation in any other concurrent clinical trial
  • Any other life-threatening, non-cardiac disease,
  • Uncontrolled hypertension (BP > 160/100 mm of Hg)
  • Congestive Heart Failure
  • Use of an investigational agent or therapeutic regimen within 30 days of study
  • Subjects on Exenatide, incretin or insulin therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00659711

United States, New York
115 Flint Road
Buffalo, New York, United States, 14221
Sponsors and Collaborators
Kaleida Health
Merck Sharp & Dohme Corp.
Principal Investigator: Paresh Dandona, MD Kaleida Health
  More Information

No publications provided

Responsible Party: Paresh Dandona, MD, MD, Kaleida Health Identifier: NCT00659711     History of Changes
Other Study ID Numbers: 1931 Januvia 
Study First Received: April 10, 2008
Last Updated: December 17, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Dipeptidyl-Peptidase IV Inhibitors
Enzyme Inhibitors
Hormones, Hormone Substitutes, and Hormone Antagonists
Hypoglycemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors processed this record on February 11, 2016